Global Stem Cells Group is expanding its international presence through a new strategic partnership with Exomagic in Tajikistan. The collaboration aims to support the development of regenerative medicine in Central Asia by connecting international physician education, biotechnology products, and regional medical professionals through ISSCA and Cellgenic.

The partnership brings together GSCG’s international physician education platform and biotechnology product portfolio with Exomagic’s regional relationships and market development activities. The collaboration will initially focus on Tajikistan, with plans to engage healthcare professionals and organizations across neighboring Central Asian countries.

The initiative follows RMTG’s international operating model, which connects physician education, professional training, and product commercialization through its Global Stem Cells Group divisions.

Cellgenic: Establishing a Biotechnology Presence in Central Asia

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group, will work alongside Exomagic to develop local commercial relationships, physician engagement, and distribution infrastructure in the region.

Cellgenic’s portfolio includes exosomes, peptides, cellular products, and related biotechnology offerings for professional markets.

The partnership will focus on product education, commercial training, technical resources, and the development of local support capabilities for healthcare professionals.

The companies intend to coordinate regional distribution activities in accordance with applicable regulatory requirements and local market conditions.

ISSCA: Bringing International Regenerative Medicine Education to Central Asia

The International Society for Stem Cell Application (ISSCA), the education and innovation division of Global Stem Cells Group, will collaborate with Exomagic to introduce its physician education programs to Central Asia.

As part of the partnership, the organizations plan to host an international regenerative medicine conference in Dushanbe, Tajikistan, bringing together physicians, healthcare professionals, researchers, and regional medical organizations.

The proposed educational program will address regenerative medicine, cellular technologies, exosome science, peptide medicine, longevity, and regenerative aesthetics.

The collaboration also includes plans for continuing professional education through specialized workshops, physician training programs, and regional educational activities. ISSCA’s participation will provide an academic component to the partnership, complementing Cellgenic’s regional commercial development.

Management Commentary

Benito Novas, Founder of Global Stem Cells Group, commented:

“We are very happy to begin this new partnership in Central Asia. Our mission has always been to make regenerative medicine knowledge and technologies more accessible to doctors and, ultimately, to the patients they serve. Through ISSCA and Cellgenic, we can bring together education, professional support, and access to biotechnology products. We look forward to working with our partners in Tajikistan and building long-term relationships with the medical community throughout the region.”

Operational and Strategic Update

The Central Asia partnership represents an additional geographic initiative within RMTG’s international activities, complementing the Company’s existing education and commercial programs in Latin America and other international markets.

The collaboration is structured around two complementary operating divisions: ISSCA, focused on physician education and training, and Cellgenic, focused on biotechnology products and commercial relationships.

The Company intends to work with Exomagic on regional implementation, including educational programming, commercial team training, and distribution planning. The timing and scope of individual activities will depend on local arrangements, operational readiness, and applicable regulatory requirements.

The Company is not providing revenue projections or financial guidance associated with this partnership.

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTCID: RMTG) is a regenerative medicine company operating through Global Stem Cells Group and its subsidiaries, combining physician education, laboratory operations, biologics manufacturing, product commercialization, and digital healthcare technologies across an international network.

Additional information about the Company’s business, operations, and risks is available in its filings with the Securities and Exchange Commission.

About Global Stem Cells Group

Global Stem Cells Group (GSCG) is an international regenerative medicine organization operating through specialized divisions focused on physician education, biotechnology products, clinical services, and professional development.

Its operating divisions include the International Society for Stem Cell Application (ISSCA) and Cellgenic.

About the International Society for Stem Cell Application (ISSCA)

The International Society for Stem Cell Application (ISSCA) is the education and innovation division of Global Stem Cells Group.

ISSCA is a multidisciplinary, physician-led community of medical professionals, researchers, professors, and scientists focused on education and scientific exchange in regenerative medicine and cellular technologies.

The organization provides physician training, certification programs, international conferences, and educational resources covering regenerative medicine and related fields.

About Cellgenic

Cellgenic is the biotechnology and product-commercialization division of Global Stem Cells Group.

Its product portfolio includes exosomes, peptides, cellular products, and related biotechnology offerings. Cellgenic works with healthcare professionals and distribution partners in international markets, providing product information, technical resources, and commercial support, subject to applicable regulatory requirements.

About Exomagic

Exomagic is a regional partner collaborating with Global Stem Cells Group on physician education, commercial development, and distribution initiatives in Central Asia.

Looking Ahead: Advancing Regenerative Medicine in Central Asia

Through this strategic partnership, Global Stem Cells Group, ISSCA, Cellgenic, and Exomagic aim to strengthen connections with the medical community in Tajikistan and neighboring countries, supporting future opportunities for physician education, scientific exchange, and biotechnology development.

Healthcare professionals, medical organizations, and potential regional partners interested in learning more about upcoming educational initiatives and collaboration opportunities are invited to visit www.RMTG.com or contact Global Stem Cells Group for further information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements concerning planned educational programs, regional expansion, distribution activities, commercial development, and future collaboration.

These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially. Factors include regulatory requirements, market conditions, operational execution, and other risks described in the Company’s filings with the Securities and Exchange Commission.

The Company undertakes no obligation to update forward-looking statements except as required by applicable law.

This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities.

Investor Relations
Regenerative Medical Technology Group, Inc.
ir@rmtg.com | (800) 956-3935
www.RMTG.com